A Phase 1 interventional study of Mirikizumab- IV and Mirikizumab - SC in Psoriasis, sponsored by Eli Lilly and Company. Completed at 2 sites in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-25.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Psoriasis by Eli Lilly and Company — 1 open to participants now, 1 under way, none of them phase 3. Psoriasis · Eli Lilly and Company.
Among the 36 studies in Psoriasis by Eli Lilly and Company, this one is the 26th largest by enrollment, is one of 3 that started in 2013, is one of 9 in phase 1, and was the 9th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →1 of the 36 studies in Psoriasis by Eli Lilly and Company is open now, in 1 country. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 181 across the 36 interventional studies. Of the 35 that completed or were terminated, 28 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 36 studies in Psoriasis by Eli Lilly and Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the safety of the study drug known as mirikizumab. The study will investigate how the body processes the study drug and how the drug affects the body. The study will last about 3 months for each participant.
Inclusion Criteria (Psoriasis participants):
Inclusion Criteria (Healthy participants):
Exclusion Criteria (Psoriasis and healthy participants):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with psoriasis will receive a single dose of placebo matching mirikizumab intravenously (IV)
Biological: Placebo - IV
Participants with psoriasis will receive a single escalating dose of 5 milligram (mg), 20 mg, 60 mg, 120 mg, 200 mg, 350 mg, or 600 mg mirikizumab, IV
Biological: Mirikizumab- IV
Healthy participants will receive a single dose of 120 mg mirikizumab subcutaneously (SC).
Biological: Mirikizumab - SC
Administered IV
Also known as: LY3074828
Administered SC
Also known as: LY3074828
Administered IV
Number of Participants With One or More Adverse Event(s) (AEs) Considered by the Investigator to Be Related to Study Drug Administration
This outcome has the list of adverse events which are related to the study drug. A summary of AEs, regardless of causality, is located in the Reported Adverse Events module.
Time frame: Baseline through Week 12
Pharmacokinetics (PK): Area Under Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3074828
Time frame: IV Arms: Day 1 Predose, Postdose (End of Infusion, 2, 6 and 24h), Days 4, 8, 15, 22, 29, 43, 57, 71, and 85. SC Arm: Day 1 Predose, Postdose (6 and 24h), Days 4, 8, 11, 15, 22, 29, 43, 57, 71, and 85
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3074828
Time frame: IV Arms: Day 1 Predose, Postdose (End of Infusion, 2, 6 and 24h), Days 4, 8, 15, 22, 29, 43, 57, 71, and 85. SC Arm: Day 1 Predose, Postdose (6 and 24h), Days 4, 8, 11, 15, 22, 29, 43, 57, 71, and 85
| Milestone | Placebo | 5 mg LY3074828 | 20 mg LY3074828 | 60 mg LY3074828 | 120 mg LY3074828 | 120 mg LY3074828 SC | 200 mg LY3074828 | 350 mg LY3074828 | 600 mg LY3074828 |
|---|---|---|---|---|---|---|---|---|---|
| Started | 7 | 3 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Completed | 7 | 3 | 4 | 5 | 5 | 5 | 5 | 5 | 4 |
| Not completed | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
This outcome has the list of adverse events which are related to the study drug. A summary of AEs, regardless of causality, is located in the Reported Adverse Events module.
| Participants | Placebo | 5 mg LY3074828 | 20 mg LY3074828 | 60 mg LY3074828 | 120 mg LY3074828 | 120 mg LY3074828 SC | 200 mg LY3074828 | 350 mg LY3074828 | 600 mg LY3074828 |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With One or More Adverse Event(s) (AEs) Considered by the Investigator to Be Related to Study Drug Administration | 1 | 1 | 2 | 0 | 0 | 3 | 1 | 0 | 0 |
| μg•day/mL (microgram•day/milliliters) | 5 mg LY3074828 | 20 mg LY3074828 | 60 mg LY3074828 | 120 mg LY3074828 | 120 mg LY3074828 SC | 200 mg LY3074828 | 350 mg LY3074828 | 600 mg LY3074828 |
|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics (PK): Area Under Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3074828 | NA ± NA | 33.6 ± 17 | 117 ± 15 | 287 ± 29 | 114 ± 49 | 366 ± 12 | 556 ± 25 | 1360 ± 23 |
| μg/mL (microgram/milliliter) | 5 mg LY3074828 | 20 mg LY3074828 | 60 mg LY3074828 | 120 mg LY3074828 | 120 mg LY3074828 SC | 200 mg LY3074828 | 350 mg LY3074828 | 600 mg LY3074828 |
|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3074828 | 1.60 ± 22 | 5.34 ± 6 | 20.6 ± 29 | 41.1 ± 15 | 7.28 ± 23 | 68.8 ± 19 | 91.8 ± 6 | 220 ± 24 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/7 (0%) | 6/7 (85.7%) |
| 5 mg LY3074828 | — | 0/3 (0%) | 3/3 (100%) |
| 20 mg LY3074828 | — | 0/5 (0%) | 5/5 (100%) |
| 60 mg LY3074828 | — | 0/5 (0%) | 5/5 (100%) |
| 120 mg LY3074828 | — | 0/5 (0%) | 2/5 (40%) |
| 120 mg LY3074828 SC | — | 0/5 (0%) | 4/5 (80%) |
| 200 mg LY3074828 | — | 0/5 (0%) | 4/5 (80%) |
| 350 mg LY3074828 | — | 0/5 (0%) | 4/5 (80%) |
| 600 mg LY3074828 | — | 0/5 (0%) | 4/5 (80%) |
| Event | Placebo | 5 mg LY3074828 | 20 mg LY3074828 | 60 mg LY3074828 | 120 mg LY3074828 | 120 mg LY3074828 SC | 200 mg LY3074828 | 350 mg LY3074828 | 600 mg LY3074828 |
|---|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 3/7 | 0/3 | 4/5 | 4/5 | 0/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| DiarrhoeaGastrointestinal disorders | 0/7 | 2/3 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 |
| Injection site painGeneral disorders | 0/7 | 0/3 | 0/5 | 0/5 | 0/5 | 3/5 | 0/5 | 0/5 | 0/5 |
| HeadacheNervous system disorders | 2/7 | 0/3 | 1/5 | 0/5 | 1/5 | 1/5 | 3/5 | 0/5 | 3/5 |
| DysmenorrhoeaReproductive system and breast disorders | 0/7 | 0/3 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | 1/2 |
| Abdominal painGastrointestinal disorders | 0/7 | 0/3 | 0/5 | 0/5 | 0/5 | 2/5 | 0/5 | 0/5 | 0/5 |
| NauseaGastrointestinal disorders | 0/7 | 0/3 | 2/5 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 |
| LacerationInjury, poisoning and procedural complications | 0/7 | 0/3 | 0/5 | 0/5 | 0/5 | 0/5 | 1/5 | 0/5 | 2/5 |
| Muscle strainInjury, poisoning and procedural complications | 0/7 | 0/3 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | 2/5 | 0/5 |
| Conjunctival haemorrhageEye disorders | 0/7 | 1/3 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 |
Safety Population: all randomized participants who received any amount of study drug.
| Age, Continuous(Years) | Placebo | 5 mg LY3074828 | 20 mg LY3074828 | 60 mg LY3074828 | 120 mg LY3074828 | 120 mg LY3074828 SC | 200 mg LY3074828 | 350 mg LY3074828 | 600 mg LY3074828 | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 44.7 ± 13.39 | 51.0 ± 13.08 | 43.4 ± 13.32 | 44.0 ± 9.14 | 43.8 ± 13.33 | 37.2 ± 13.33 | 53.2 ± 14.55 | 37.4 ± 11.37 | 42.2 ± 10.57 | 43.8 ± 12.37 |
| Sex: Female, Male(Participants) | Placebo | 5 mg LY3074828 | 20 mg LY3074828 | 60 mg LY3074828 | 120 mg LY3074828 | 120 mg LY3074828 SC | 200 mg LY3074828 | 350 mg LY3074828 | 600 mg LY3074828 | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 2 | 4 | 0 | 2 | 5 | 2 | 1 | 2 | 18 |
| Male | 7 | 1 | 1 | 5 | 3 | 0 | 3 | 4 | 3 | 27 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 5 mg LY3074828 | 20 mg LY3074828 | 60 mg LY3074828 | 120 mg LY3074828 | 120 mg LY3074828 SC | 200 mg LY3074828 | 350 mg LY3074828 | 600 mg LY3074828 | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Not Hispanic or Latino | 7 | 3 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 44 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | 5 mg LY3074828 | 20 mg LY3074828 | 60 mg LY3074828 | 120 mg LY3074828 | 120 mg LY3074828 SC | 200 mg LY3074828 | 350 mg LY3074828 | 600 mg LY3074828 | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 7 | 3 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 45 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo | 5 mg LY3074828 | 20 mg LY3074828 | 60 mg LY3074828 | 120 mg LY3074828 | 120 mg LY3074828 SC | 200 mg LY3074828 | 350 mg LY3074828 | 600 mg LY3074828 | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Canada | 7 | 3 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 45 |
The record gives a start of Oct 2013, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2024, 9 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirikizumab